Clinical Trials Logo

Filter by:
NCT ID: NCT00948389 Terminated - Glioblastoma Clinical Trials

Study of CCNU (Lomustine) Plus Dasatinib in Recurrent Glioblastoma (GBM)

Start date: October 2009
Phase: Phase 1/Phase 2
Study type: Interventional

To determine whether dasatinib plus lomustine are effective for treatment of recurrent glioblastoma

NCT ID: NCT00941707 Terminated - Clinical trials for Rheumatoid Arthritis

An Efficacy and Safety Study of JNJ-38518168 in Adult Participants With Rheumatoid Arthritis

Start date: February 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy, tolerability and safety of JNJ-38518168 compared with placebo in adult participants with active rheumatoid arthritis (long time systemic disease of the joints, marked by inflammatory changes in the synovial membranes and bones) despite methotrexate (MTX) therapy.

NCT ID: NCT00940979 Terminated - Clinical trials for Arterial Obstructive Diseases

Trial Using Integuseal as Microbial Sealant for Arterial Bypass Surgery on Lower Extremities

ITT
Start date: January 2010
Phase: N/A
Study type: Interventional

The purpose of this study is to prove a reduction of postoperative wound infections after direct preoperative use of a microbial sealant in the form of Integuseal for vascular procedures on lower extremities.

NCT ID: NCT00940095 Terminated - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Clazosentan in Aneurysmal Subarachnoid Hemorrhage

CONSCIOUS-3
Start date: July 1, 2009
Phase: Phase 3
Study type: Interventional

The aim of this study is to demonstrate that clazosentan, administered as a continuous intravenous infusion at either 5 mg/h or 15 mg/h until Day 14 post aneurysmal subarachnoid hemorrhage (aSAH), reduces the incidence of cerebral vasospasm-related morbidity and all-cause mortality within 6 weeks post-aSAH treated by endovascular coiling. The primary endpoint of the study is the occurrence of cerebral vasospasm-related morbidity, and mortality of all-causes within 6 weeks post-aSAH, defined by at least one of the following: 1. Death (all causes). 2. New cerebral infarct(s) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm. 3. Delayed ischemic neurological deficit (DIND) due to cerebral vasospasm as either the primary or relevant contributing cause, or not adjudicated to be entirely due to causes other than vasospasm. 4. Administration of a valid rescue therapy in the presence of confirmed cerebral vasospasm on angiography (DSA or CTA). An independent Critical Events Committee (CEC) will adjudicate whether or not patients meet the primary endpoint and its individual morbidity components.

NCT ID: NCT00936559 Terminated - Rotator Cuff Tear Clinical Trials

Study Evaluating Safety Of BMP-655/ACS As An Adjuvant Therapy For Rotator Cuff Repair

Start date: September 2010
Phase: Phase 1
Study type: Interventional

Study to assess the safety of 3 differing concentrations of BMP-655/ACS in subjects with full thickness Rotator Cuff Tears (RCTs).

NCT ID: NCT00930969 Terminated - Clinical trials for Coronary Artery Disease

ST Segment Detection Study

ST Detect
Start date: April 2008
Phase:
Study type: Observational

The purpose of ST Detect study is to evaluate whether naturally occurring spontaneous coronary events and exercise induced cardiac ischemia, give rise to detectable changes on intracardiac electrogram (EGM) signals in patients that are indicated for an Implantable Cardioverter Defibrillator (ICD) who have coronary artery disease.

NCT ID: NCT00929019 Terminated - Uveal Melanoma Clinical Trials

Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients

Start date: June 2009
Phase: Phase 1/Phase 2
Study type: Interventional

1. Rationale Immunotherapy applying ex vivo generated and tumor antigen-loaded dendritic cells (DC) has now successfully been introduced in the clinic. A limited, but consistent, number of objective immunological and clinical responses have been observed. Most of the successful results have been observed in patients with minimal residual disease, rather than patients with advanced metastatic disease. Moreover, the investigators' preliminary results show that presence of tumor epitope specific T cells in biopsies taken from delayed type hypersensitivity (DTH) reaction sites highly correlates with prolonged progression free survival (PFS). Within uveal melanoma patients, a group with high risk of metastatic disease can be identified on basis of tumor specific genetic changes in loss of chromosome 3. At present no standard adjuvant or systemic treatment is available. Applying DC-based immunotherapy in this group of high risk patients might reduce the risk of recurrence without interference in the current treatment guidelines. 2. Objectives In this joint clinical study of Radboud University Nijmegen Medical Centre (RUNMC) and Rotterdam Eye Hospital, the investigators aim to determine the in vivo immunological response induced in high risk uveal melanoma patients vaccinated with mRNA-transfected DC. 3. Study design This study is an open label non-randomized phase II intervention study. 4. Study population The investigators' study population consists of HLA-A2 positive patients with a high risk uveal melanoma with proven expression of melanoma associated antigens tyrosinase and/or gp100. 5. Main study endpoints This is an exploratory study aiming to demonstrate proof of principle. The first study endpoints are in vivo immunological response induced in high risk uveal melanoma patients vaccinated with mRNA-transfected DC, administered i.v./i.d. and toxicity. Secondary study endpoints are progression free survival, overall survival, and toxicity.

NCT ID: NCT00922844 Terminated - Hypotension Clinical Trials

The Effect of Sevoflurane Versus Isoflurane on Vasopressor Need

ESIVAN
Start date: May 2009
Phase: Phase 4
Study type: Interventional

Aim of this study is to determine the effect of isoflurane versus sevoflurane on blood pressure and systemic vascular resistance.

NCT ID: NCT00920582 Terminated - Clinical trials for Type 1 Diabetes Mellitus

Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

Start date: September 2009
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to determine whether teplizumab (MGA031) infusions lead to greater reductions in insulin requirements in conjunction with near normal blood sugar control compared to placebo in patients recently diagnosed with type 1 diabetes.

NCT ID: NCT00913510 Terminated - Multiple Sclerosis Clinical Trials

Efficacy of Clean Intermittent Catheterization (CIC) in Multiple Sclerosis (MS) Patients With Bladder Dysfunction

Start date: December 2009
Phase: N/A
Study type: Interventional

The aims of this prospective, randomized study are: - To assess the effect of clean intermittent catheterization (CIC) - To investigate if MS patients will have symptom reduction (urgency, frequency, nocturia and incontinence) when using CIC in combination with anticholinergic drugs - To identify at what volume of Postvoid Residual (PVR) urine, starting CIC improves bladder control and QoL - To increase the evidence of CIC, and support clinical guidelines of bladder management in MS patients